...
首页> 外文期刊>Journal of Neuroscience Research >Intrathecal administration of sigma-1 receptor agonists facilitates nociception: involvement of a protein kinase C-dependent pathway.
【24h】

Intrathecal administration of sigma-1 receptor agonists facilitates nociception: involvement of a protein kinase C-dependent pathway.

机译:鞘内注射sigma-1受体激动剂可促进伤害感受:参与蛋白激酶C依赖性途径。

获取原文
获取原文并翻译 | 示例
           

摘要

Sigma sites, originally proposed as opioid receptor subtypes, are currently thought to represent unique receptors with a specific pattern of drug selectivity, a well-established anatomical distribution and broad range of functional roles including potential involvement in nociceptive mechanisms. We have recently demonstrated that intrathecal (i.t.) treatment with a sigma-1 receptor antagonist reduced formalin-induced pain behavior. In the present study, we investigated the potential role of spinal sigma-1 receptor agonists in peripherally initiated nociception and attempted to elucidate intracellular signaling mechanisms associated with spinal cord sigma-1 receptor activation in mice. The i.t. injection of the sigma-1 receptor agonists PRE-084 (PRE) or carbetapentane (CAR) significantly decreased tail-flick latency (TFL) and increased the frequency of paw withdrawal responses to mechanical stimulation (von Frey filament, 0.6 g) as well as the amount of Fos expression in the spinal cord dorsal horn induced by noxious paw-pinch stimulation. These PRE- or CAR-induced facilitatory effects on nociception were significantly blocked by i.t. pretreatment with the sigma-1 receptor antagonist, BD-1047, the phospholipase C (PLC) inhibitor, U-73,122, the Ca(2+)-ATPase inhibitor, thapsigargin, and the protein kinase C (PKC) inhibitor, chelerythrine. Western blot analysis further revealed that i.t. PRE or CAR injection significantly increased pan-PKC as well as the PKCalpha, epsilon, and zeta isoforms in the dorsal horn. Collectively, these findings demonstrate that calcium-dependent second messenger cascades including PKC are involved in the facilitation of nociception associated with spinal sigma-1 receptor activation.
机译:最初被提议为阿片样物质受体亚型的西格玛位点目前被认为代表具有特定药物选择性模式,公认的解剖学分布和广泛的功能性作用(包括潜在参与伤害感受机制)的独特受体。我们最近证实,鞘内(i.t.)用sigma-1受体拮抗剂治疗可减少福尔马林引起的疼痛行为。在本研究中,我们调查了脊髓sigma-1受体激动剂在周围引发伤害感受中的潜在作用,并试图阐明小鼠中与脊髓sigma-1受体激活相关的细胞内信号传导机制。 i.t.注射sigma-1受体激动剂PRE-084(PRE)或carbetapentane(CAR)显着降低了甩尾潜伏期(TFL),并增加了对机械刺激的爪缩回反应的频率(冯·弗雷丝,0.6 g)以及有害的爪捏刺激在脊髓背角中的Fos表达量。这些PRE或CAR诱导的伤害感受促进作用被i.t.用sigma-1受体拮抗剂BD-1047,磷脂酶C(PLC)抑制剂,U-73,122,Ca(2 +)-ATPase抑制剂,thapsigargin和蛋白激酶C(PKC)抑制剂白屈菜红碱进行预处理。蛋白质印迹分析进一步揭示了PRE或CAR注射显着增加了背角的pan-PKC以及PKCalpha,ε和zeta亚型。总的来说,这些发现表明,包括PKC在内的钙依赖性第二信使级联参与了与脊髓sigma-1受体激活相关的伤害感受的促进。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号